Key facts
- This page summarizes W. Mark Watson's Form 4 filing for Vaxart, Inc. (VXRT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Aug 2022, 18:39.
W. Mark Watson - 04 Aug 2022 Form 4 Insider Report for Vaxart, Inc. (VXRT)
- Reporting relationship
- Director
- Issuer ticker
- VXRT
- Reported as of
- 04 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Aug 2022, 18:39:08 UTC
- Prior SEC filing
- 14 Jun 2022
- Next SEC filing
- 28 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward Berg, Attorney-in-Fact for W. Mark Watson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
W. Mark Watson filed Form 4 for Vaxart, Inc. (VXRT) on 08 Aug 2022.
Change
- Previous filing in this sequence was filed on 14 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VXRT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +14,750
- Change %
- Price
- $0.000000
- Shares after
- 14,750
- Date
- 04 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VXRT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +88,448
- Change %
- Price
- $0.000000
- Shares after
- 88,448
- Date
- 04 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 88,448
- Exercise price
- $3.91
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Grant of shares upon vesting of restricted stock units. One third of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the third anniversary of the grant date.
Footnote F2
The shares subject to this option shall vest annually over three years from the vesting commencement date of August 4, 2022, the date of the grantee's appointment as a director of Vaxart, Inc.